BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35149000)

  • 1. Predominance of Staphylococcus Correlates with Wound Burden and Disease Activity in Dystrophic Epidermolysis Bullosa: A Prospective Case-Control Study.
    Reimer-Taschenbrecker A; Künstner A; Hirose M; Hübner S; Gewert S; Ibrahim S; Busch H; Has C
    J Invest Dermatol; 2022 Aug; 142(8):2117-2127.e8. PubMed ID: 35149000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case Report of an Infant with Autosomal Recessive Dystrophic Epidermolysis Bullosa: COL7A1 Gene Mutations at C2005T and G7922A.
    Liu J; Wang L
    Acta Dermatovenerol Croat; 2021 Dec; 29(3):164-166. PubMed ID: 34990346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphological and morphometric analysis of cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a retrospective study.
    Filoni A; Cicco G; Lospalluti L; Maglietta A; Foti C; Annichiarico G; Resta L; Bonamonte D
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1707-1714. PubMed ID: 31692111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal study of wound healing status and bacterial colonisation of Staphylococcus aureus and Corynebacterium diphtheriae in epidermolysis bullosa patients.
    Fuentes I; Yubero MJ; Morandé P; Varela C; Oróstica K; Acevedo F; Rebolledo-Jaramillo B; Arancibia E; Porte L; Palisson F
    Int Wound J; 2023 Mar; 20(3):774-783. PubMed ID: 36787273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.
    Tang JY; Marinkovich MP; Lucas E; Gorell E; Chiou A; Lu Y; Gillon J; Patel D; Rudin D
    Orphanet J Rare Dis; 2021 Apr; 16(1):175. PubMed ID: 33849616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for cutaneous dysbiosis in dystrophic epidermolysis bullosa.
    Bar J; Sarig O; Lotan-Pompan M; Dassa B; Miodovnik M; Weinberger A; Sprecher E; Segal E; Samuelov L
    Clin Exp Dermatol; 2021 Oct; 46(7):1223-1229. PubMed ID: 33682945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab.
    Zhang L; Wang S; Chen Q; Xiang L
    J Dermatolog Treat; 2023 Dec; 34(1):2253943. PubMed ID: 37968922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral microbiome in children with dystrophic recessive epidermolysis bullosa].
    Korolenkova MV; Poberezhnaya AA; Dmitrieva NA
    Stomatologiia (Mosk); 2022; 101(1):46-52. PubMed ID: 35184533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey.
    Eng VA; Solis DC; Gorell ES; Choi S; Nazaroff J; Li S; de Souza MP; Murrell DF; Marinkovich MP; Tang JY
    J Am Acad Dermatol; 2021 Nov; 85(5):1161-1167. PubMed ID: 32199895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant dystrophic epidermolysis bullosa with congenital absence of skin and brachydactyly of the great toes.
    Sawka E; Funk T
    Pediatr Dermatol; 2021 Sep; 38(5):1251-1254. PubMed ID: 34338359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired secretory immunity in dystrophic epidermolysis bullosa.
    Sweet SP; Ballsdon AE; Harris JC; Roberts GJ; Challacombe SJ
    Oral Microbiol Immunol; 1999 Oct; 14(5):316-20. PubMed ID: 10551159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations.
    McGrath JA; Ashton GH; Mellerio JE; Salas-Alanis JC; Swensson O; McMillan JR; Eady RA
    J Invest Dermatol; 1999 Sep; 113(3):314-21. PubMed ID: 10469327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human skin collagenase in recessive dystrophic epidermolysis bullosa. Purification of a mutant enzyme from fibroblast cultures.
    Stricklin GP; Welgus HG; Bauer EA
    J Clin Invest; 1982 Jun; 69(6):1373-83. PubMed ID: 6282934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin expression of metalloproteinases and tissue inhibitor of metalloproteinases in sibling patients with recessive dystrophic epidermolysis and intrafamilial phenotypic variation.
    Bodemer C; Tchen SI; Ghomrasseni S; Séguier S; Gaultier F; Fraitag S; de Prost Y; Godeau G
    J Invest Dermatol; 2003 Aug; 121(2):273-9. PubMed ID: 12880418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gluten-sensitive enteropathy in recessive dystrophic epidermolysis bullosa.
    Sacedón R; de Arriba MC; Martínez-Santamaría L; Maseda R; Herráiz-Gil S; Jiménez E; Rosales I; Quintana L; Illera N; García M; Butta N; Fernández-Bello I; Lwin SM; Fernández-Arquero M; León C; McGrath JA; Vicente MÁ; Del Río M; de Lucas R; Sánchez-Ramón S; Escámez MJ
    Br J Dermatol; 2023 Nov; 189(6):774-776. PubMed ID: 37655918
    [No Abstract]   [Full Text] [Related]  

  • 16. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.
    Wagner JE; Ishida-Yamamoto A; McGrath JA; Hordinsky M; Keene DR; Woodley DT; Chen M; Riddle MJ; Osborn MJ; Lund T; Dolan M; Blazar BR; Tolar J
    N Engl J Med; 2010 Aug; 363(7):629-39. PubMed ID: 20818854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural variations in anchoring fibrils in dystrophic epidermolysis bullosa: correlation with type VII collagen expression.
    McGrath JA; Ishida-Yamamoto A; O'Grady A; Leigh IM; Eady RA
    J Invest Dermatol; 1993 Apr; 100(4):366-72. PubMed ID: 8454899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey.
    Fulchand S; Harris N; Li S; Barriga M; Gorell E; De Souza M; Murrell D; Marinkovich MP; Krishna Yenamandra V; Tang JY
    Pediatr Dermatol; 2021 Sep; 38(5):1198-1201. PubMed ID: 34515355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participatory co-design of patient-reported outcome indicators and N-of-1 evaluation of a dressing glove for Epidermolysis bullosa.
    Graham T; Sooriah S; Box R; Gage H; Williams P; Clemett V; Grocott P
    J Wound Care; 2020 Dec; 29(12):751-762. PubMed ID: 33320744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identical COL71A1 heterozygous mutations resulting in different dystrophic epidermolysis bullosa phenotypes.
    Knöpfel N; Noguera-Morel L; Hernández-Martin A; García-Martin A; García M; Mencía Á; Pedrero RM; de Lucas R; Escámez MJ; Torrelo A
    Pediatr Dermatol; 2018 Mar; 35(2):e94-e98. PubMed ID: 29272047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.